Pharma giant Moderna has raised its 2021 sales forecast for its COVID-19 vaccine by 4.3% to $19.2bn, reflecting the strong demand for rapid inoculation across the world.
In February this year, Moderna had forecasted vaccine sales of $18.4bn.
However, wealthy nations have been stocking up shots from vaccine producers such as Moderna and Pfizer after safety concerns and production problems temporarily stalled AstraZeneca and Johnson & Johnson vaccines.
In the first quarter to end of March, Moderna's vaccine brought in sales of $1.7bn.
The company said it plans to file for full approval of the vaccine in the US this month.
There are concerns for Moderna though with the US market. Earlier this week the Biden administration voiced support for waiving patent rights covering COVID-19 vaccines.
The share price of Moderna and other vaccine manufacturers fell in late trading on Wednesday in response.
The Biden administration may negotiate with the World Trade Organisation to discuss waiving patent protection for the vaccines.
The WTO has called for member nations to temporarily ease patent protections for COVID-19 vaccines. This would allow other countries to manufacture vaccines using the same technological processes as companies like Moderna and AstraZeneca.